Schott Pharma (stylized as SCHOTT Pharma) is a provider of drug containment solutions and delivery systems for injectable drugs.[2][3] Originally a division of glass manufacturer Schott AG, the company went public on the Frankfurt Stock Exchange in 2023.[4] Headquartered in Mainz, Germany,[5][6] the company operates in 14 countries.[7]
History
Filling Schott glass ampoules with medications (1932)Schott & Gen. advertisement for borosilicate glass vials (1923)
In 1887, Otto Schott developed borosilicate glass, a form of glassware used to reagent bottles and flasks. From 1911, Schott manufactured borosilicate glass tubing for the production of pharmaceutical ampoules and vials.[8]
Schott Pharma was established as a standalone company in 2022 under the name Schott Pharma AG & Co. KGaA[9][6] through an equity carve-out (or spin-off) from Schott AG, a manufacturer of specialty glass and glass-ceramics.[10][11] In the same year, the company announced their plans to present an IPO, but this was reportedly postponed to 2023 due to the Russian invasion of Ukraine.[5]
In June 2023, Schott Pharma announced plans to hold the IPO in September 2023.[12] This plan was enacted in September, with Schott Pharma going public on the Frankfurt Stock Exchange.[13] The IPO was initially priced at 27€ per share,[14][15] and a potential valuation of up to 4.1 billion euros,[16] but increased the share price to 30€ the following day.[17][13] The IPO was the largest of the year in Germany.[18][19] In December 2023, Schott Pharma was included in the SDAX.[20] In September 2024, Schott Pharma was promoted to the MDAX.[21]
Production & Manufacturing
This section needs expansion. You can help by adding to it. (June 2024)
The company is headquartered in Mainz and operates in 16 locations across 14 countries.[22]
Europe
Müllhein, Germany (Müllheim Production and Technology Centre)[23][24]
Schott Pharma develops and manufactures drug containment solutions and delivery systems for injectable drugs, which it supplies to companies in the biotechnology and pharmaceutical industries.[31]
Its business is divided into two divisions:
Drug Containment Solutions: pharmaceutical vials, cartridges, and glass ampoules[32]
Drug Delivery Systems: prefillable glass syringes and syringes made from Cyclic olefin copolymers (COC), suitable for deep-cold medications.[33]
Prefillable glass syringe
Prefillable polymer syringe
Ampoule
Vial
Cartridge
Governance
Schott Pharma is a subsidiary of SCHOTT AG, which holds controlling shares (as of 2023: 77%).[19][17] SCHOTT AG is owned by the Carl Zeiss Foundation.[25]
Schott Pharma is listed on the Frankfurt Stock Exchange's MDAX.[21]
This section needs expansion. You can help by adding to it. (June 2024)
Independent Supervisory Board
In 2023 SCHOTT AG appointed a Supervisory Board for the subsidiary Schott Parma AG as follows:[34][35]
Peter Goldschmidt, (Chairman)
Dr. Wolfgang Wienand (Chairman of the Executive Board of Siegfried Holding AG)
Eva Kienle (CFO of KWS Saat SE & Co. KGaA)
Ann-Kristin Erkens (Corporate Senior Vice President, Financial and Business Controlling at Henkel Adhesive Technologies)
^Wilkes, William; Gopinath, Swetha (2023-06-22). "Schott to Hold IPO of Medical Glassware Unit in September: Bloomberg.com". Bloomberg.com: N.PAG–N.PAG.
^ ab"Schott Pharma trades up following biggest German IPO since Porsche: Global Capital". Global Capital: N.PAG–N.PAG. 2023-10-16.
^ abRuhkamp, Christoph (2024-10-04). "Finanzchefin bringt Schott Pharma in den MDax" [Chief Financial Officer brings Schott Pharma into the MDax]. boersen-zeitung.de (in German). Retrieved 2024-11-04.
^ abHerpai, Gergely (2024-07-12). "Schott Pharma's HUF 28 bln Investment Boosts Hungarian Pharmaceutical Manufacturing: Budapest Business Journal". Budapest Business Journal. 32 (14): 8–8.
^"Schott Pharma Begins Construction on Serbia Plant: American Ceramic Society Bulletin". American Ceramic Society Bulletin. 103 (5): 49–49. July 2024.
![[icon]](File:Wiki_letter_w_cropped.svg){kind=small}
